8-K: Corvus Pharma Presents Promising Soquelitinib Data in Atopic Dermatitis

Corvus Pharmaceuticals announced positive final data from a Phase 1 trial of soquelitinib for atopic dermatitis, showing safety, efficacy, and potential for durable, drug-free remissions.

Summary

• Corvus Pharmaceuticals presented final data from a Phase 1 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis.
• The trial enrolled 72 patients, with 35% having previously failed systemic therapy.
• Soquelitinib demonstrated positive safety and efficacy, with no significant safety issues reported across all cohorts.
• Adverse events were Grade 1-2 and occurred in 41.7% of soquelitinib patients and 41.7% of placebo patients.
• Key efficacy results in cohorts 3 and 4 (200 mg twice daily) showed up to 75% of patients achieving EASI 75 and 33% achieving IGA 0/1.
• Disease control was maintained throughout post-treatment follow-up periods (30-90 days) with no observed disease rebound or need for rescue medication.
• Biomarker data supports soquelitinib's mechanism of action, including potential for drug-free remissions by modulating T cell function and increasing Treg cells.
• A Phase 2 trial (SIERRA1) is currently enrolling approximately 200 patients, and a Phase 1b/2 trial is ongoing with Angel Pharmaceuticals in China.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with strong preliminary efficacy and safety data, and supportive biomarker results, indicating good potential for the drug candidate.

Positives

• Demonstrated positive safety profile with no severe or serious adverse events reported.
• Achieved significant efficacy endpoints, with up to 75% of patients in Cohort 4 achieving EASI 75.
• Showed durable disease control and remission during post-treatment follow-up periods (30-90 days) without rebound.
• Biomarker data supports the novel mechanism of action, including potential for drug-free remissions.
• Efficacy was observed in patients who had previously failed systemic therapy.
• Dose-dependent efficacy trends were noted in cohorts 1-3.
• Additional clinical benefit was observed with longer treatment in cohort 4.
• No rescue medications were required during the follow-up periods.

Negatives

• Efficacy rates, while promising, still leave a significant portion of patients not achieving target endpoints (e.g., EASI 75, IGA 0/1).
• The trial was a Phase 1 study, and larger, confirmatory trials are needed to validate these findings.
• While adverse events were mild, they were comparable to placebo (41.7% vs 41.7%).

Risks

• The accuracy of estimates relating to the ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials.
• The results of preclinical studies and interim data from clinical trials not being predictive of future results.
• The Company's ability to enroll sufficient numbers of patients in its clinical trials.
• The unpredictability of the regulatory process.
• Regulatory developments in the United States and foreign countries.
• The costs of clinical trials may exceed expectations.
• The Company's ability to accurately estimate the cash on hand providing funding into the second quarter of 2028 and the Company's ability to raise additional capital.

Future Outlook

The company is advancing soquelitinib into Phase 2 trials for atopic dermatitis and has a Phase 3 trial for relapsed/refractory PTCL. The company also has other clinical-stage candidates for various cancer indications. The company estimates its cash on hand provides funding into the second quarter of 2028 and is focused on its ability to raise additional capital.

Management Comments

• "There is a need for a safe oral systemic therapy that can address these limitations and be effective across the disease spectrum including relapsed/refractory patients. The results of this trial are exciting as they suggest that soquelitinib may meet this need, with the possibility of offering shorter treatment regimens and prolonged disease clearance for patients."
• "The biomarker data demonstrates the translation between soquelitinibs mechanism of action and its clinical activity. The immunologic markers are consistent with soquelitinibs mechanism of action and the clinical results from the Phase 1 trial. The data supports the effects of soquelitinib on multiple T cell properties including cytokine production, inflammatory cell function and the induction of persistent Tregs. The data also provides support for the findings of the lack of disease rebound observed in treated patients."
• "The soquelitinib Phase 1 data shows the potential of ITK inhibition to treat a broad range of atopic dermatitis patients, including those who are resistant to other systemic therapies. Biomarker data supports soquelitinibs novel mechanism of action, demonstrating the ability to modulate several key cellular functions that are not currently targeted by approved and in development systemic therapies. The data also supports the potential for soquelitinib to be a novel treatment for a range of autoimmune and inflammatory diseases based on a rebalancing of immunity, which could reduce the need for chronic long-term therapy. We believe that soquelitinib may have the potential to change the underlying biology of these diseases."

Industry Context

StockSavvy.ai notes that the positive Phase 1 data for soquelitinib in atopic dermatitis aligns with the industry trend of developing targeted immunotherapies for autoimmune and inflammatory diseases. The potential for durable, drug-free remissions and a favorable safety profile, if validated in later-stage trials, could position soquelitinib as a differentiated treatment option against existing therapies that often require chronic administration and can have significant side effects.

Comparison to Industry Standards

• Published data from approved systemic therapies for atopic dermatitis typically show a worsening or rebound of disease within four weeks of stopping therapy, often requiring rescue medication. Soquelitinib demonstrated sustained disease control for 30-90 days post-treatment without rebound or need for rescue medication.
• Efficacy rates in Cohort 4 (75% EASI 75, 33% IGA 0/1) are competitive with or exceed those reported for some approved systemic therapies in similar patient populations, though direct comparisons are limited due to differences in trial design and patient populations.

Stakeholder Impact

• Shareholders: Positive data may increase investor confidence and potentially impact stock price.
• Patients: Potential for a new, effective treatment option for moderate-to-severe atopic dermatitis with a favorable profile.
• Healthcare Providers: May offer a new therapeutic option with potential for shorter treatment courses and durable remissions.

Next Steps

• Continue enrollment in the SIERRA1 Phase 2 clinical trial for soquelitinib in atopic dermatitis.
• Continue enrollment in the Phase 1b/2 clinical trial with Angel Pharmaceuticals in China.
• Analyze results from ongoing and future clinical trials to support further development.
• Potentially advance soquelitinib to later-stage clinical trials based on continued positive data.

Key Dates

Recommendation

The Phase 1 data is promising, showing good safety and efficacy signals, and the potential for durable remissions. However, it is still early-stage data. While positive, it warrants a 'hold' recommendation until further validation in larger Phase 2 and Phase 3 trials confirms these findings and demonstrates a clear clinical advantage over existing therapies.

Keywords

soquelitinib, atopic dermatitis, Phase 1 trial, Corvus Pharmaceuticals, ITK inhibitor, eczema, immunotherapy, clinical data